Anzeige
Mehr »
Login
Donnerstag, 30.05.2024 Börsentäglich über 12.000 News von 688 internationalen Medien
Die neuen Aktien-Stars der nächsten Rallye-Stufe im Uransektor
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A3C2EY | ISIN: US04635X1028 | Ticker-Symbol: 2090
Tradegate
29.05.24
15:41 Uhr
8,100 Euro
-0,200
-2,41 %
Branche
Pharma
Aktienmarkt
Sonstige
1-Jahres-Chart
ASTRIA THERAPEUTICS INC Chart 1 Jahr
5-Tage-Chart
ASTRIA THERAPEUTICS INC 5-Tage-Chart
RealtimeGeldBriefZeit
8,2008,45017:42

Aktuelle News zur ASTRIA THERAPEUTICS Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
23.05.Astria Therapeutics, Inc.: Astria Therapeutics to Present at Upcoming European Academy of Allergy and Clinical Immunology Congress166Astria Therapeutics, Inc. (NASDAQ:ATXS), a biopharmaceutical company focused on developing life-changing therapies for allergic and immunological diseases, today announced that it will present two...
► Artikel lesen
10.05.Astria TherapeuticS GAAP EPS of -$0.38 misses by $0.027
09.05.Astria Therapeutics Reports First Quarter 2024 Financial Results and Provides a Corporate Update164BOSTON--(BUSINESS WIRE)--Astria Therapeutics, Inc. (NASDAQ:ATXS), a biopharmaceutical company focused on developing life-changing therapies for allergic and immunological diseases, today reported...
► Artikel lesen
09.05.Astria Therapeutics, Inc. - 10-Q, Quarterly Report1
09.04.Astria Therapeutics, Inc. - 8-K, Current Report5
25.03.Astria Therapeutics Reports Positive Initial Results From ALPHA-STAR Trial20
25.03.Astria Therapeutics, Inc. - 8-K, Current Report2
04.03.Astria Therapeutics GAAP EPS of -$2.42 misses by $0.1913
04.03.Astria Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides a Corporate Update170BOSTON--(BUSINESS WIRE)--Astria Therapeutics, Inc. (NASDAQ:ATXS), a biopharmaceutical company focused on developing life-changing therapies for allergic and immunological diseases, today reported...
► Artikel lesen
04.03.Astria Therapeutics, Inc. - 10-K, Annual Report2
06.02.Astria Therapeutics 10% owner Perceptive Advisors discloses purchase of 2.48M shares19
30.01.Astria Therapeutics stock jumps on pricing of $125M underwritten offering27
30.01.Astria Therapeutics, Inc. - 8-K, Current Report9
05.01.Astria Therapeutics, Inc. - 8-K, Current Report10
20.12.23Astria Therapeutics, Inc. - 8-K, Current Report7
15.12.23Astria Therapeutics files $500M mixed securities shelf14
13.11.23Astria Therapeutics Reports Third Quarter Financial Results and Provides a Corporate Update320BOSTON--(BUSINESS WIRE)--Astria Therapeutics, Inc. (NASDAQ:ATXS), a biopharmaceutical company focused on developing life-changing therapies for rare and niche allergic and immunological diseases...
► Artikel lesen
09.11.23Astria Therapeutics, Inc.: Astria Therapeutics to Present at Upcoming Jefferies London Healthcare Conference360Astria Therapeutics, Inc. (Nasdaq:ATXS), a biopharmaceutical company focused on developing life-changing therapies for allergic and immunological diseases, today announced that Jill C. Milne, Ph.D....
► Artikel lesen
07.08.23Astria Therapeutics Reports Second Quarter Financial Results and Provides a Corporate Update261BOSTON--(BUSINESS WIRE)--Astria Therapeutics, Inc. (NASDAQ:ATXS), a biopharmaceutical company developing STAR-0215 for the treatment of hereditary angioedema (HAE) and focused on life-changing...
► Artikel lesen
05.06.23Astria Therapeutics, Inc.: Astria Therapeutics to Present STAR-0215 at the 2023 European Academy of Allergy, Asthma, and Immunology Annual Meeting554Astria Therapeutics, Inc. (Nasdaq:ATXS), a biopharmaceutical company developing STAR-0215 for the treatment of hereditary angioedema and focused on life-changing therapies for rare and niche allergic...
► Artikel lesen
20 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1